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OBJECTIVE Granulocyte-colony stimulating factor (G-CSF) is a major cytokine that has already been clinically verified 
for chronic traumatic spinal cord injuries (TSCIs). In this study, the authors set out to determine the safety and efficacy of 
G-CSF administration for neurological and functional improvement in subacute, incomplete TSCI.
METHODS This phase II/III, prospective, double-blind, placebo-controlled, parallel randomized clinical trial was 
performed in 60 eligible patients (30 treatment, 30 placebo). Patients with incomplete subacute TSCIs with American 
Spinal Injury Association Impairment Scale (AIS) grades B, C, and D were enrolled. Patients were assessed using the 
International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) scale, Spinal Cord Independence 
Measure (SCIM-III) and International Association of Neurorestoratology Spinal Cord Injury Functional Rating Scale 
(IANR-SCIFRS), just before intervention and at 1, 3, and 6 months, after 7 daily subcutaneous administrations of 300 μg/
day of G-CSF in the treatment group and placebo in the control group.
RESULTS Among 60 participants, 28 patients (93.3%) in the G-CSF group and 26 patients (86.6%) in the placebo 
group completed the study protocol. After 6 months of follow-up, the AIS grade remained unchanged in the placebo 
group, while in the G-CSF group 5 patients (45.5%) improved from AIS grade B to C, 5 (45.5%) improved from AIS grade 
C to grade D, and 1 patient (16.7%) improved from AIS grade D to E. The mean ± SEM change in ISNCSCI motor score 
in the G-CSF group was 14.9 ± 2.6 points, which was significantly greater than in the placebo group (1.4 ± 0.34 points, 
p < 0.001). The mean ± SEM light-touch and pinprick sensory scores improved by 8.8 ± 1.9 and 10.7 ± 2.6 points in the 
G-CSF group, while those in the placebo group improved by 2.5 ± 0.60 and 1.2 ± 0.40 points, (p = 0.005 and 0.002, re-
spectively). Evaluation of functional improvement according to the IANR-SCIFRS instrument revealed significantly more 
functional improvement in the G-CSF group (10.3 ± 1.3 points than in the placebo group (3.0 ± 0.81 points; p < 0.001). 
A significant difference was also observed between the 2 groups as measured by the SCIM-III instrument (29.6 ± 4.1 vs 
10.3 ± 2.2, p < 0.001).
CONCLUSIONS Incomplete subacute TSCI is associated with significant motor, sensory, and functional improvement 
after administration of G-CSF.
Clinical trial registration no.: IRCT201407177441N3 (www.irct.ir)
https://thejns.org/doi/abs/10.3171/2018.6.SPINE18209
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TraumaTic spinal cord injury (TSCI) produces dev-astating physical, social, and vocational impair-ment.2 Despite the availability of advanced re-
habilitation modalities, there remains a need to explore 
therapeutic strategies for treating TSCI patients by cellu-
lar and/or molecular mechanisms modifying the patho-
physiology of TSCI. New therapeutic approaches involve 
strategies aimed at blocking multiple mechanisms of pro-
gressive pathogenesis of secondary TSCI.37 The primary 
injury event starts a pathobiological cascade of secondary 
mechanisms that unfold in different phases, beginning 
within seconds of the primary trauma, and may continue 
for several weeks thereafter.38
Secondary injury may be an appropriate target for neu-
roprotective and clinical therapeutic interventions,12,37 such 
as methylprednisolone sodium succinate (MPSS) and the 
related compound tirilazad mesylate,4,9 nimodipine,24 nal-
oxone,10 gancyclidine (N-methyl-d-aspartate antagonist),32 
and granulocyte colony-stimulating factor (G-CSF).6,14, 
27,33 G-CSF has already been reported to have positive ef-
fects on the course of various neurological disorders ex-
perimentally, such as stroke,30 Parkinson’s disease,20 Alz-
heimer’s disease,34 amyotrophic lateral sclerosis,23 sciatic 
nerve injury,17 partial cochlear nerve lesion,21 traumatic 
brain injury,31 and various rodent models of TSCI.22
Multiple preclinical studies in TSCI models have sug-
gested several mechanisms for the neurorestorative ef-
fects of G-CSF, including antiapoptotic activity, stem cell 
mobilization, angiogenesis, neurogenesis, and immuno-
modulation through specific signaling pathways.18 Various 
authors have reported on G-CSF regarding its wide neu-
roprotective action and its neurodegenerative mechanisms 
of action in the treatment of TSCI.18 G-CSF has been suc-
cessfully used clinically for acute14,33 and chronic6,27 TSCI, 
as well as subacute compressive myelopathy28,29 and stroke 
in humans.25
Previously, on the basis of the available preclinical 
and clinical results described, we have conducted phase 
I,6 phase I/IIa,27 and phase III7 clinical trials with promis-
ing results regarding safety, feasibility, and efficacy of G-
CSF as a neuroprotective therapy in patients with chronic 
TSCI. In this trial, a phase II/III study, we attempt to de-
termine the safety and verify the efficacy of subcutaneous 
G-CSF in comparison with placebo, for the treatment of 
subacute incomplete TSCI and compare neurological as 
well as functional outcomes between the 2 groups.
Methods
Study Design
This phase II/III, prospective, double-blind, placebo-
controlled, parallel randomized clinical trial, was conduct-
ed from August 2014 to June 2017 in the Brain and Spinal 
cord Injury Research (BASIR) Center at Imam Khomeini 
Hospital, Tehran University of Medical Sciences (TUMS). 
The local institutional review board/ethics committee of 
TUMS approved the trial. In addition, the study was reg-
istered in the Iranian Registry of Clinical Trials (IRCT; 
registration no. IRCT201407177441N3, www.irct.ir) before 
enrollment of the participants. The study protocol adheres 
to the criteria of the revised Consolidated Standards of Re-
porting Trials’ (CONSORT) 2010 statement. The study was 
conducted in compliance with the seventh revision of the 
Declaration of Helsinki and the international conference 
on harmonization of Good Clinical Practice guidelines.
The patients were selected among outpatient TSCI cas-
es in the BASIR Center at Imam Hospital, TUMS. Sixty 
eligible patients with subacute incomplete TSCI were cho-
sen and enrolled after providing written informed consent 
for the study. At the screening visits, demographic and 
clinical assessments were performed by obtaining the 
patient’s history, performing a physical examination, and 
reviewing the images.
Baseline evaluations included duration of injury, neu-
rological level, severity of injury according to the Ameri-
can Spinal Injury Association (ASIA) Impairment Scale 
(AIS) grade (A–E), surgical approach, and concurrent 
complications. Neurological complications were evalu-
ated as follows: neuropathic pain using the visual analog 
scale (VAS; score range 0–100) and spasticity using the 
Modified Ashworth Scale (MAS; score range 0–4). Neu-
rological changes were assessed using the International 
Standards for Neurological Classification of Spinal Cord 
Injury (ISNCSCI) scale designed by ASIA (motor scores 
range 0–100, light touch scores range 0–112, and pinprick 
scores range 0–112.19 Functional changes were assessed 
using the the Spinal Cord Independence Measure III 
(SCIM-III; score range 0–100)15 as well as the Internation-
al Association of Neurorestoratology Spinal Cord Injury 
Functional Rating Scale (IANR-SCIFRS; score range 
0–4),13 to evaluate the ability to perform basic daily tasks.
Study Participants
At the screening visits, the demographic and clinical 
assessments and the severity of TSCI based on AIS grad-
ing were recorded as baseline measurements. Participants 
between 18 and 60 years of age were enrolled in the study. 
Patients with incomplete (AIS grade B–D) TSCIs of be-
tween 1 and 6 months’ duration (subacute phase) were se-
lected. All patients had undergone decompression and sta-
bilization, if necessary, in the acute setting. They also had 
been evaluated with postoperative CT scanning to ensure 
proper screw placement and MRI to ensure adequacy of 
the surgical decompression of the spinal canal at the same 
center or at our center if necessary. Neurological exami-
nation was performed, and those with upper motor neu-
ron–type injury (Babinski sign and hyperreflexia) without 
evidence of lower motor neuron involvement (absence of 
significant muscle atrophy) were selected. Electrodiagnos-
tic examination was performed to rule out disuse atrophy, 
if necessary. All patients stated that they were available 
to undergo the entire length of follow-up. Patients were 
excluded if they had active major complications associated 
with the TSCI or systemic associated illness.
Patients were selected among those referred to the 
outpatient rehabilitation clinic of BASIR Center. They 
were chosen during the 1.5-year recruitment period; 342 
patients of the 402 patients were excluded in accordance 
with the CONSORT flow diagram (Fig. 1). Three hundred 
thirty patients did not meet inclusion criteria for the fol-
lowing reasons: duration of TSCI more than 6 months 
(chronic disease; n = 214), complete SCI injury (AIS grade 
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A; n = 92), did not meet age requirements (n = 7), associ-
ated brain injury (contusion and/or diffuse axonal injury; 
n = 2), fracture of the humerus bone that led to radial 
nerve injury and wrist drop (n = 1), heterotopic ossifica-
tion (n = 3), complicated untreated grade 4 pressure sores 
(n = 2), pneumonia (n = 2), deep vein thrombosis (n = 4), 
metallic implant failure (n = 2), and platelet abnormality 
(n = 1). Finally, 72 patients were found to be eligible, of 
whom 4 patients declined to participate and 8 patients had 
traveling difficulties to the center because of high cervi-
cal spinal cord injury or prolonged travel times. In total, 
60 patients with TSCI were included (30 in the treatment 
group and 30 in the control group). They were randomly 
allocated into the study groups according to the study pro-
tocol as follows.
Study Protocol
After obtaining informed consent, a complete blood 
count (CBC) sample was obtained, and patients underwent 
thorough neurological assessment using the ISNCSCI sen-
sorimotor scale.19 Functional assessment was performed 
using the SCIM-III15 and IANR-SCIFRS.13 Random al-
location was performed using a computer-generated list 
obtained by an investigator with no clinical involvement in 
the trial. Patients were then randomized according to ran-
dom block design and were allocated to the study groups 
using the sealed-envelope method. This was performed 
by an independent staff nurse who assigned the partici-
pants to the allocated interventions. Participants were 
primarily evaluated neurologically by an experienced 
neurosurgeon. Functional evaluations were performed by 
a trained physician. Patients and clinical evaluators were 
blinded with regard to the treatment groups, i.e., G-CSF 
and placebo vials had the same cover shape but different 
codes. In the treatment group, the injected vial contained 
300 μg G-CSF (filgrastim, Neupogen, Amgen) that was 
administered subcutaneously around the umbilicus with 
at least 2 inches of distance daily for 7 consecutive days 
by experienced nursing staff on an outpatient basis. In the 
control group the injected vial contained 1 ml of normal 
saline 0.9%, and the same treatment protocol was adhered 
to. All of these personnel were independent and unaware 
(blinded) of the treatment group assignment.
CBC with differential white blood cell (WBC) and 
platelet counts were performed at regular intervals (daily) 
2–3 hours after injection, up to 7 days. The blood test was 
performed again at 3- and 6-month intervals after treat-
ment to assess any chronic hematological side effects. For 
FIG. 1. CONSORT flow diagram for trial profile.
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ethics concerns, if the 3 first CBC examination findings 
were normal, the test was not repeated. The control group 
had 3 CBC tests, but the main researchers were unaware 
of their WBC count details. Possible side effects of inter-
vention were scrutinized by an independent nursing staff 
and recorded. At the 1-, 3-, and 6-month follow-up visits, 
the patients were assessed for functional and neurologi-
cal status, as well as possible secondary complications, 
including spasticity and neuropathic pain. In all cases, 
there was a single examiner for neurological assessment 
and another for the functional assessment from first to last 
follow-up visits; therefore, it was not necessary to perform 
an interrater reliability analysis.
All patients underwent a uniform simultaneous out-
patient rehabilitation program consisting of a multidis-
ciplinary education program that was begun during the 
baseline visit, with follow-ups at 1, 3, and 6 months, com-
bined with twice-weekly physical therapy together with 
occupational therapy as a rehabilitation package for 6 
months after intervention. For handling any missing data, 
the last-observation-carried-forward method was used. 
This method replaces every missing value with the last 
observed value from the same patient. There was no de-
viation from the protocol.
Primary and Secondary Outcome Measures
Our primary outcome measure was neurological 
change based on ISNCSCI scores, after subcutaneous G-
CSF administration under investigation at a dose of 300 
μg/day for 7 consecutive days, compared with a placebo, 
for subacute incomplete TSCIs. Motor and sensory score 
changes measured using the ISNCSCI scale19 from be-
fore treatment and in the follow-up visits were considered 
as the primary outcome measure. Functional changes, 
as evaluated by SCIM-III15 and IANR-SCIFRS13 before 
treatment and during follow-up visits were considered as 
secondary outcome measures. Safety was also evaluated 
as an important outcome measure. Any evidence of side 
effects was recorded regularly and reported by the inde-
pendent observers during the 1st year after intervention.
Stopping guidelines for treatment included a WBC 
count > 50,000/μl on CBC, any sign of hypersensitivity 
reactions and/or significant thrombocytopenia (platelet 
count < 100,000/μl of blood). Both were indications for 
discontinuation of the injections.
Sixty patients were randomized and allocated to the 
2 groups (30 patients each). In the treatment group, one 
patient with AIS grade C cervical TSCI did not receive al-
located intervention and died of respiratory failure due to 
Klebsiella pneumonia leading to septicemia, and another 
patient with AIS grade C was lost to follow-up because of 
new travel problems. In the control group, one patient with 
AIS grade C thoracic TSCI did not receive allocated inter-
vention and died following a complicated gastrostomy. In 
addition, 3 patients (2 with AIS grade C and 1 with AIS 
grade D) were lost to follow-up due to new travel prob-
lems. None of the cases lost to follow-up reported any side 
effects on regular phone calls. Therefore, we had 10% at-
trition rate between the randomization and last follow-up; 
54 (90%) patients completed the follow-up period. There 
were no missing data for these patients. Analysis included 
28 (11 AIS grade B, 11 AIS grade C, and 6 AIS grade D) 
patients in the G-CSF group and 26 (11 AIS grade B, 9 
AIS grade C, and 6 AIS D) patients in the placebo group.
Statistical Analysis
Descriptive results are presented as the mean ± SD for 
continuous variables and frequency with percentage for 
categorical variables. Statistical comparison of qualitative 
variables between the 2 groups was performed using the 
chi-square or Fisher’s exact test, where appropriate. Quan-
titative variables in the G-CSF and placebo groups were 
compared using the independent sample t-test or Mann-
Whitney test, as appropriate. The extent of AIS grade im-
provement, before treatment and at the 6-month follow-up, 
was compared between the 2 groups using the chi-square 
test.
The mean ± SEM for outcome measures, including 
ISNCSCI motor, light touch, and pinprick scores; SCIM-
III scores; and IANR-SCIFRS scores, were calculated, 
and the changes were reported. ANCOVA was used for 
comparing the change in outcome measure in the 2 groups 
with treatment group as the fixed effect, and baseline 
score as the covariate; p < 0.05 was considered as statisti-
cally significant. The sample size was calculated to detect 
5-point differences in the SCIM-III mean change1 between 
the 2 groups, with 85% statistical power and 5% type 1 er-
ror. Thirty patients were estimated for each group.
Results
Patient Characteristics
From August 2014 up to February 2016, 60 patients 
(mean age ± SD 34.0 ± 12.6 years) at a single center were 
randomized into 2 groups: 30 patients to the G-CSF group 
and 30 patients to the placebo group. The overall male/
female ratio was 9:1. The follow-up period was 1 year after 
recruitment for each case. Twenty-eight patients (93.3%) 
in the G-CSF group and 26 patients (86.6%) in the placebo 
group completed the study protocol (Fig. 1).
The mean age of the participants was 36.5 ± 13.3 in the 
G-CSF group and 31.0 ± 9.9 years in the placebo group. 
There were 89.3% males in the G-CSF group and 92.3% 
males in the placebo group. There were no significant 
differences in demographic and clinical characteristics 
between the study groups (Table 1). Comparison of AIS 
grades did not show a significant difference between cer-
vical cases (p = 0.118) and thoracolumbar cases (p = 0.412).
Neurological Assessment
There were no statistically significant differences in the 
baseline ISNCSCI motor and sensory scores between the 
G-CSF and placebo groups (Fig. 2). After 6 months of fol-
low-up, the mean ± SEM change in ISNCSCI motor score 
in the G-CSF group was 14.9 ± 2.6, which was signifi-
cantly higher than that in the placebo group (1.4 ± 0.34) 
(p < 0.001). Also, there was significant improvement in 
mean ± SEM light-touch score (8.8 ± 1.9 vs 2.5 ± 0.60, p = 
0.005) and pinprick sensory score (10.7 ± 2.6 vs 1.2 ± 0.40, 
p = 0.002) in the G-CSF and placebo groups, respectively.
Regarding AIS grade, 5 patients (45.5%) with AIS 
grade B improved to AIS grade C, while 6 patients (54.5%) 
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TABLE 1. Demographic and clinical characteristics of patients in the G-CSF and placebo groups
G-CSF Group (n = 28) Placebo Group (n = 26) p Value
Mean age at time of injection, yrs 36.5 (13.3) 31.0 (9.9) 0.096
Male sex 25 (89.3%) 24 (92.3%) >0.90
Mean duration after SCI, mos 3.7 (1.97)    3.9 (1.77) 0.754
Mean education, yrs 9.7 (5.6) 10.9 (4.4) 0.416
Marital status
0.847 Single 9 (32.1%) 9 (34.6%)
 Married 19 (67.9%) 17 (65.4%)
Occupation status
0.340
 Employed 6 (21.4%) 5 (19.2%)
 Left job (temporary)/fired 18 (64.3%) 13 (50.0%)
 Retired 4 (14.3%) 8 (30.8%)
Etiology of SCI
0.718
 MVA 14 (50.0%) 14 (53.8%)
 Fall 10 (35.7%) 8 (30.8%)
 Sport 1 (3.6%) 2 (7.7%)
 Violence 1 (3.6 %) 2 (7.7%)
 Heavy drop 2 (7.1%) 0 (0.0%)
Neurological level of injury
0.554 Cervical 13 (46.4%) 10 (38.5%)
 Thoracolumbar 15 (53.6%) 16 (61.5%)
AIS grade
0.939
 B 11 (39.3%) 11 (42.3%)
 C 11 (39.3%) 9 (34.6%)
 D 6 (21.4%) 6 (23.1%)
Mean lesion length on T1WI, mm    15.36 (10.9) 16.63 (9.1) 0.656
Median timing of surgical decompression, days 3 (1–9) 2 (1–8.7) 0.825
 Early surgical decompression (≤24 hrs) 8 (28.5%) 11 (42.3%)
0.431 Late surgical decompression (>24 hrs) 19 (67.9%) 13 (50.0%)
 No surgery 1 (3.6%) 2 (7.7%)
Surgical techniques
0.899
 Pst laminectomy & stabilization (pedicle screw) 16 (57.2%) 13 (50.0%)
 Ant corpectomy & stabilization (cage & plate or screw) 3 (10.7%) 5 (19.2%)
 Pst transpedicluar corpectomy & stabilization 0 (0.0%) 1 (3.8%)
 Combined approach (ant & pst) 2 (7.1%) 1 (3.8%)
 Traction & pst stabilization 2 (7.1%) 1 (3.8%)
 Traction & ant stabilization 3 (10.7%) 3 (11.6%)
 Laminectomy (for laminar fracture) 1 (3.6%) 0 (0.0%)
 Conservative (traumatic cervical central cord syndrome) 1 (3.6%) 2 (7.7%)
Median no. of instrumented segments 3 (2–4) 4 (3–4) 0.284
Rehabilitation status before study
 Rehabilitation at home 13 (46.5%) 15 (57.7%)
0.684 Outpatient rehabilitation 9 (32.1%) 6 (23.1%)
 No rehabilitation 6 (21.4%) 5 (19.2%)
 Mean duration, mos 2.6 (2.1) 2.0 (1.8) 0.304
Mean WBC count, µl
 Before treatment 7511 (1980) 7252 (1580) 0.600
 After treatment 28,453 (9806) 8138 (4393) <0.001
Ant = anterior; MVA = motor vehicle accident; pst = posterior; T1WI = T1-weighted imaging.
Values are presented as the number of patients (%) unless stated otherwise. Mean values are presented as the mean (SD). Median values are 
presented as the median (IQR).
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remained unchanged. In AIS grade C patients, 5 patients 
(45.5%) improved to AIS grade D, and 6 patients (54.5%) 
were unchanged. In AIS grade D patients, 1 patient (16.7%) 
improved to AIS grade E, and 5 patients (83.3%) remained 
unchanged (Fig. 3A). There were no changes in AIS grade 
in the placebo group. Overall, 11 (39.3%) of the 28 patients 
in the G-CSF group had a 1-grade improvement in their 
AIS grade compared with no AIS changes in the place-
bo group, a difference that was statistically significant (p 
< 0.001). In the G-CSF group, the AIS grade improved 
in 38.4% of patients with cervical injuries and in 40% 
of those with thoracolumbar injuries. We found that the 
duration of injury had a significant effect on motor score 
changes (p < 0.001) but not on sensory changes (p > 0.2).
Functional Assessment
Evaluation of functional outcomes using the IANR-
SCIFRS instrument revealed significant changes in the 
G-CSF group (10.3 ± 1.3 points), in comparison with 
the placebo group (3.0 ± 0.81 points, p < 0.001). In addi-
tion, assessment using the SCIM-III instrument showed a 
significant difference in functional changes between the 
2 groups (29.6 ± 4.1 vs 10.3 ± 2.2 points, p < 0.001). No 
statistically significant difference was observed in the 
baseline measurements of the total value of SCIM-III and 
IANR-SCIFRS scores between the G-CSF and placebo 
groups (Fig. 3B and C). The mean progressive functional 
assessments are shown in Fig. 4. Regarding SCIM-III (Fig. 
4A) and IANR-SCIFRS (Fig. 4B) subscale changes, pa-
tients in the G-CSF group had significant improvement in 
comparison to those in the placebo group.
Subgroup Analysis
A subgroup analysis for cervical and thoracolumbar 
regions was performed between the 2 groups (intergroup 
analysis). The analysis showed significant differences 
among all neurological and functional changes, in both 
cervical and thoracolumbar subgroups, between the G-
CSF and placebo cases, with the exception of the light-
touch score change in cervical subgroup (p = 0.07, near to 
significant; Table 2). Intragroup analysis of G-CSF cases 
showed greater changes in motor (p = 0.037) and pinprick 
(borderline significant, p = 0.051) scores in the cervical 
subgroup than in the thoracolumbar subgroup (Table 3). 
Also intragroup analysis for early and late surgical de-
compression in the G-CSF group showed nonsignificant 
changes in motor, pinprick, SCIM-III, and FRS scores. 
Changes in light-touch scores, however, were significant 
in the early decompression subgroup (p = 0.012, Table 3).
White Blood Cell Count
The CBC was performed before, as well as daily after, 
each injection. The mean ± SD postinjection WBC count 
in G-CSF group was 28,453 ± 9806/μl and 8136 ± 4393 
μl in the placebo group. There was a significant increase 
in WBC in the G-CSF group compared with the placebo 
group (p < 0.001).
Systemic Side Effects
In the G-CSF group, there were 2 (7.1%) individuals 
FIG. 2. Comparison of ISNCSCI scores. A: ISNCSCI motor scores. 
There was no significant difference between the groups before treat-
ment (p = 0.645); statistical significance was observed 6 months after 
treatment (p < 0.001). B: ISNCSCI light-touch scores. There was no sig-
nificant difference between the groups before treatment (p = 0.651); sta-
tistical significance was observed 6 months after treatment (p = 0.002). 
C: ISNCSCI pinprick scores of the 2 groups. There was no significant 
difference between the groups before treatment (p = 0.267); statistical 
significance was observed 6 months after treatment (p < 0.001). Values 
are means with SEM denoted by the error bars.
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with mild to moderate bone pain, 2 (7.1%) cases of tran-
sient pruritus and skin rash, 1 (3.5%) fever, and 1 (3.5%) 
patient with left upper quadrant pain, without spleno-
megaly on ultrasonography. All systemic complications 
subsided spontaneously for at most 1 week after the last 
dose of G-CSF. There were no systemic side effects in the 
placebo group.
Neuropathic Pain and Spasticity
Three (10.7%) patients in the G-CSF group experienced 
increased neuropathic pain. Two patients had 20-point and 1 
patient had 10-point increases in severity of pain according 
to the VAS score approximately 6 months after injection. 
This complication lasted up to 1 year but was amenable to 
GABA [gamma-aminobutyric acid] receptor agonist dose 
adjustment. Two (7.1%) patients showed increased spastic-
ity. Spasticity increased, approximately 1–2 points based 
on the MAS, in one case after 1 month, and the other case 
6 months postinjection. In the first case, the MAS score 
returned to the pretreatment value after 6 months. Another 
patient (3.5%) showed increased frequency of spastic epi-
sodes that were controlled by conservative management. 
On the other hand, 6 (21.4%) patients showed decreased 
neuropathic pain (20–50 points in VAS score) from 3 to 
6 months after injections. Two (7.1%) patients showed de-
creased spasticity; one had a 1-point decrease (based on the 
MAS score), and the other patient experienced a reduced 
number of spasticity episodes in the 6-month follow-up.
In the placebo group, 2 (8.6%) patients reported new 
neuropathic pain. There were 2 (7.6%) individuals with in-
creased spasticity 3 to 6 months after placebo injection. In 
addition, 1 (3.8%) patient showed decreased neuropathic 
pain of approximately 40 points (based on VAS).
Discussion
Conducting phase III randomized clinical trials, when 
possible, has always been an important step for the estab-
lishment of new therapeutic modalities. Blindness and 
randomizations, when plausible, establish class I evidence 
for the disputed treatment, which is why we carried out the 
current study.
Prognostication
The neurological severity of the TSCI determines a given 
patient’s basal neurological status on admission, and conse-
quently this is the strongest prognostic marker.37 Therefore, 
patients with incomplete TSCI may be the best candidates 
for neurorestorative treatments, provided that the delivered 
substance or cells are biologically safe and the route of de-
livery is minimally invasive. With the same rationale, we 
chose incomplete (AIS grade B–D) TSCIs for this study 
and considered subcutaneous G-CSF as a safe interven-
tion.6 According to our results, the greatest change in AIS 
grade in the G-CSF group was observed among AIS grade 
B and C patients. However, improvement in AIS grade D 
was less common than in AIS grade B or C patients.
Neurological Assessment
Authors of most studies did not assess their cases with 
objective methods for neurological assessments, while 
others reported objective neurological outcomes, such as 
results of electrophysiological studies (electromyography, 
nerve conduction studies, somatosensory evoked poten-
tials, and motor evoked potentials),26 urodynamic studies, 
MR myelography,36 diffusion tensor imaging,40 and serum 
FIG. 3. A: Percentage of AIS changes at final assessment in the G-CSF 
group. There were no significant changes in AIS grade in the placebo 
group. B: Comparison of the SCIM scores. No significant difference was 
noted before treatment (p = 0.136); statistical significance was observed 
6 months after treatment (p < 0.001). C: Comparison of the IANR-
SCIFRS (FRS) scores. No significant difference before treatment (p = 
0.219); statistical significance was observed 6 months after treatment (p 
< 0.001). Values in B and C are means with SEM denoted by the error 
bars.
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and cerebrospinal fluid biomarkers.5,35 It seems that most 
authors accept ISNCSCI as the gold-standard neurological 
assessment, so this method was used for outcome report 
in our study.
Timing
The timing of neurorestorative treatments may have 
a great influence on outcome; it is one of the important 
prognosticators and sometimes a key condition for the de-
cision to treat. Regarding the effect of duration of TSCI on 
outcome, we have compared our results for subacute TSCI 
with those from our earlier report on chronic TSCI in 
terms of ISNCSCI, SCIM III, and IANR-SCIFRS scores 
(Fig. 5).7 Better outcomes in the subacute setting may not 
FIG. 4. Comparison of functional status at 6 months. A: SCIM score; all changes were statistically significant (p < 0.05) except for 
bathing lower body, use of toilet, bed-wheelchair transfer, and ground-wheelchair transfer. B: IANR-SCIFRS; all changes were 
statistically significant (p < 0.05) except for bathing, sweating, and skin condition.
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only be due to the treatment effect size but also as a result 
of autorecovery mechanisms in subacute TSCI.8 Autore-
covery is explicitly the cause of all neurological improve-
ments in our control group and some of the changes in the 
G-CSF group. The rate of autorecovery is a function of 
neurological severity (AIS).8
Another important aspect of the therapeutic time win-
dow for neurorestorative intervention is that the majority 
of patients may arrive in the hospital several hours after 
the onset of injury, especially in underdeveloped health-
care settings.18 The wide therapeutic time window of G-
CSF treatement may be beneficial in unpredictable cir-
cumstances.
Side Effects
Complications and side effects of various neurorestor-
ative treatments may be either due to the specific type of 
cell and/or drug applied or as result of the route of treat-
ment delivery. The long-term reported adverse effects 
include accentuation of neuropathic pain, spasticity, auto-
nomic dysreflexia, myelomalacia, and encephalomyelitis. 
Transient reported untoward effects include neurological 
deterioration, aseptic meningitis, leakage of cerebrospinal 
fluid, fever, headache, skin rash, and hepatic dysfunction.26
Mild symptoms after G-CSF administration include 
low-back and pelvic pain, fever, chills, headache, rash, 
nausea, vomiting, and mild hepatic dysfunction. Symp-
toms have been transient and disappeared 2 to 7 days after 
cessation of the drug.3,6,14 In our series, patients reported 
transient bone pain, rash, pruritus, and left upper quadrant 
pain. Moreover, in our study, increased neuropathic pain 
(10.7%) and spasticity (7.1%) were among the persistent 
but treatable side effects. Overall, the dose (300 μg/day), 
duration (7 consecutive days), and route (subcutaneous in-
jection) of G-CSF administration employed in the present 
study are generally safe and tolerable for use in subacute 
incomplete TSCI.
Combination Therapy
Combined neuroprotective and neuroregenerative strat-
egies are most likely effective steps moving forward in 
tackling the multifaceted nature of the injury; however, 
this approach requires tailoring to specific patient sub-
TABLE 2. Subgroup analysis of change in neurological (based 
on ISNCSCI) and functional (based on SCIM-III and FRS) scores 
in G-CSF and placebo groups according to neurological 
level (cervical or thoracolumbar) and timing of surgical 











 No. of patients 13 10
 ΔMotor score 20.8 ± 4.0 2.3 ± 0.66 0.001
 ΔLight-touch score 11.5 ± 3.7 3.3 ± 1.2 0.07
 ΔPinprick score 16.3 ± 5.3 1.3 ± 0.88 0.02
 ΔSCIM III score 22.0 ± 5.9 3.2 ± 1.2 0.01
 ΔIANR-SCIFRS score 8.9 ± 2.0 1.4 ± 0.87 0.007
Thoracolumbar level
 No. of patients 15 16
 ΔMotor score 9.8 ± 3.0 0.93 ± 0.32 0.005
 ΔLight-touch score 6.5 ± 1.7 2.1 ± 0.59 0.02
 ΔPinprick score 5.8 ± 1.2 1.2 ± 0.40 0.001
 ΔSCIM III score 36.2 ± 5.4 14.8 ± 3.1 0.002
 ΔIANR-SCIFRS score 11.5 ± 1.7 4.0 ± 1.1 0.001
Early surgical decompression 
(≤24 hrs)*
  No. of patients
  ΔMotor score 19.1 ± 4.8 1.8 ± 0.67 0.001
  ΔLight-touch score 16.7 ± 5.0 3.0 ± 0.76 0.006
  ΔPinprick score 17.8 ± 8.7 2.0 ± 0.89 0.047
  ΔSCIM III score 22.5 ± 7.5 10.9 ± 3.3 0.139
  ΔIANR-SCIFRS score 7.5 ± 1.8 3.0 ± 1.2 0.054
Late surgical decompression 
(>24 hrs)*
  No. of patients 19 13
  ΔMotor score 13.0 ± 3.3 1.3 ± 0.38 0.007
  ΔLight-touch score 5.9 ± 1.5 2.3 ± 1.0 0.095
  ΔPinprick score 7.8 ± 1.4 0.84 ± 0.24 <0.001
  ΔSCIM III score 31.6 ± 5.1 9.6 ± 3.6 0.003
  ΔIANR-SCIFRS score 11.3 ± 1.7 2.8 ± 1.2 0.001
Δ = change from baseline to 6 months posttreatment.
Values are presented as the mean ± SEM unless noted otherwise.
* Surgical decompression was not performed in 1 patient in the G-CSF group 
and 2 patients in the placebo group.
TABLE 3. Subgroup analysis of changes in the neurological 
(ISNCSCI) and functional (SCIM-III and IANR-SCIFRS) scores in 









No. of patients 13 15
ΔMotor score 20.8 ± 4.0 9.8 ± 3.0 0.037
ΔLight-touch score 11.5 ± 3.7 6.5 ± 1.7 0.213
ΔPinprick score 16.3 ± 5.3 5.8 ± 1.2 0.051
ΔSCIM III score 22.07 ± 5.9 36.2 ± 4.1 0.092







Group (>24 hrs) 
p 
Value
No. of patients 8 19
ΔMotor score 19.1 ± 4.8 13.0 ± 3.3 0.325
ΔLight-touch score 16.7 ± 5.0 5.9 ± 1.5 0.012
ΔPinprick score 17.8 ± 8.7 7.8 ± 1.4 0.104
ΔSCIM III score 22.5 ± 7.5 31.6 ± 5.1 0.338
ΔIANR-SCIFRS score 7.5 ± 1.8 11.3 ± 1.7 0.215
* One patient did not undergo decompression.
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groups.2 MPSS commonly is administered within the first 
24 hours after TSCI.9 G-CSF benefits from a much longer 
therapeutic time window and may be administered later in 
the subacute phase.28,29 Comparative studies have observed 
greater ISNCSCI motor score changes in a G-CSF group 
compared with an MPSS group.33 In addition, on 2 other 
studies16,33 of patients with acute TSCI, the incidence of 
pneumonia in the MPSS group was significantly greater 
than in the G-CSF group. There seems to be no contrain-
dication for administration of the 2 drugs in the same per-
son, i.e., they may be given to the same patient but at dif-
ferent times following trauma. The far superior safety and 
tolerability profile of G-CSF make it a suitable potential 
adjunct to MPSS after the acute phase of SCI treatment.
Cervical and Thoracolumbar Subgroups
Subgroup analysis of our findings (Table 3) showed a sig-
nificant difference in neurological and functional outcomes 
between cervical and thoracolumbar cases, although both 
subgroups benefit from treatment. This finding is concor-
dant with those of Wu et al.39 (acidic fibroblast growth fac-
tor), and Grossman et al.11 (riluzole). Also, better response 
was observed in our cervical cases in the G-CSF group, 
similar to the results of the Casha et al.5 (minocycline) study.
Strengths
With the randomized controlled design with parallel 
assigned, concealed allocation, and double-blindness of 
examiners and participants in our study, we have tried to 
eliminate the risks of systematic bias; selection bias; bias 
of patient background and baseline neurological and func-
tional status difference (baseline imbalance) of the treat-
ment arms; the impact of placebo effect; participant bias; 
and measurement bias and exclude the effect of autorecov-
ery in the G-CSF group.
The G-CSF and placebo groups were treated at a single 
institution with the same method of rehabilitation, and/or 
time periods. Hence, treatment consistency between the 2 
groups has not been compromised.
The pathophysiology and symptoms of TSCI may vary, 
depending on the spinal level of injury (cervical or thora-
columbar), as well as the severity of the trauma measured 
by the AIS. We tried to exlude this effect in our study by 
eliminating selection bias between the two groups. Further 
analysis revealed that the initial AIS grade and neurologi-
cal level of injury were the same between the 2 groups due 
to the random block design of the study. Also, this study 
had minimal attrition bias (10%), with 90% of patients 
having complete follow-up and minimal missing data due 
to regular contacts and follow-up visit appointment re-
minders.
Regarding cost-effectiveness of the treatment, subcu-
taneous G-CSF administration may be administered dur-
ing hospital admission, especially in subacute cases on an 
FIG. 5. Comparison of neurological (based on ISNCSCI) and functional (based on SCIM-III and FRS) score changes in subacute 
(this study) versus chronic (our previous study7) TSCIs treated with G-CSF.
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outpatient basis, provided that the patient is cooperative 
and well instructed. Interobserver bias was minimal in 
this study because all examinations were performed by 
constant evaluators during the study for neurological and 
functional assessments.
Limitations
There is a probability of information bias due to ob-
server errors of assessment tools, including the ISNCSCI, 
SCIM III, and IANR-SCIFRS. Another limitation is that 
4 patients were lost to follow-up and 2 patients died before 
receiving allocated intervention. We tried to minimize 
their number with periodic phone calls for fixing the as-
sessment meetings with the patient. Finally, we should 
mention that the total number of included patients was 
relatively small.
Conclusions
Incomplete subacute TSCI is associated with signifi-
cant motor, sensory, and functional improvement due to 
autorecovery, which this may be significantly promoted by 
G-CSF administration. Further multicenter trials would be 
the next step for establishment of the results.
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